All articles by Akosua Mireku

Akosua Mireku


Akosua Mireku is a healthcare reporter for Pharmaceutical Technology. Akosua has a Bsc in medical physiology from the University of Manchester. She is particularly interested in topics in neuroscience, rare diseases, and global health equality

Intellia propels into 2024 with CRISPR pipeline updates

Intellia Therapeutics announced its clinical goals for the next few years, pushing development for its late-stage ATTR asset.

Innate Pharma forges ahead with lacutamab trial post-FDA investigation

The FDA removes a partial clinical hold for Innate’s lacutamab trials following an investigation of a patient’s death.

BMS bags advanced melanoma win for Opdualag in the UK

The MHRA gave Bristol Myers Squibb’s Opdualag marketing authorisation for advanced melanoma as part of Project Orbis.

ARTBIO divulges plans for proprietary isotope manufacturing technology

ARTBIO is developing a proprietary radiotherapy manufacturing technology to overcome distribution and supply chain challenges.

Difficult biotech investment ecosystem forces focus on value

In 2023, investors pursued pharmaceutical assets with value amidst an unstable economic environment.

FDA revamps EUA guidance for Covid-19 monoclonal antibodies

The FDA released an updated guidance for developing Covid-19 monoclonal antibody treatments for EUAs as variants evolve.

Kronos Bio swivels focus towards multiple myeloma after AML failure

Kronos Bio is prioritising its multiple myeloma therapy after reviewing negative Phase Ib AML data for lanraplenib.

Pharma readies for climate disasters amidst supply chain concerns

Experts discussed the potential impacts of climate change on the pharma supply chain and how companies can prepare for them.

Ironwood seals the deal on VectivBio merger

Ironwood Pharmaceuticals completed an acquisition of the gastrointestinal disease company VectivBio.

Pliant Therapeutics recruits patients for bexotegrast trial amidst lPF race

Pliant Therapeutics doubles down on enrolment for a Phase IIb IPF trial as other industry players also investigate new IPF therapies.